{"nctId":"NCT01337986","briefTitle":"Ampyra for Optic Neuritis in Multiple Sclerosis","startDateStruct":{"date":"2011-05"},"conditions":["Multiple Sclerosis","Optic Neuritis"],"count":53,"armGroups":[{"label":"Group B: Dalfampridine First","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dalfampridine/Placebo"]},{"label":"Group A: Dalfampridine Second","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo/Dalfampridine"]}],"interventions":[{"name":"Dalfampridine/Placebo","otherNames":["Ampyra (R)","Fampridine"]},{"name":"Placebo/Dalfampridine","otherNames":["Ampyra (R)","Fampridine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria are:\n\n1. At least one previous clinical episode of optic neuritis,\n2. the last episode of ON must have occurred at least 12 months prior to study entry,\n3. clinically definite MS, defined by the revised McDonald criteria, 23\n4. ages 18-70,\n5. visual acuity greater than or equal to 20/30\n6. must be able to read at least 2 of the 5 letters on the top line of the 5% ETDRS chart (logMAR 0.96) at 3 meters, 2 meters or 1 meter, and\n7. must have sufficient cognitive function to understand the consent process and to reliably perform all clinical assessments\n\nExclusion criteria are:\n\n1. Any ophthalmologic condition, other than ON, which can affect vision, including nystagmus in primary position of gaze,\n2. history of seizures or spells with altered level of consciousness,\n3. pregnancy or breast feeding,\n4. an MS exacerbation or use of glucocorticoids within 3 months of entry,\n5. a history of moderate to severe renal insufficiency,\n6. previous use of 4-aminopyridine, in any formulation, in the prior 4 weeks.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores","description":"Per Protocol Analysis to assess differences in EDTRS 5% Contrast Sensitivity (LogMAR) Scores at visits 2 and 3 Relative to Visit 1 on patients taking Dalfampridine vs Placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.02"},{"groupId":"OG001","value":"-0.06","spread":"0.02"},{"groupId":"OG002","value":"-0.08","spread":"0.02"},{"groupId":"OG003","value":"-0.06","spread":"0.02"}]}]}]},{"type":"PRIMARY","title":"Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity","description":"Per Protocol Analysis to assess difference in number of letters on the EDTRS 5% Contrast Sensitivity (LogMAR) Chart scores at visits 2 and 3 Relative to Visit 1","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"1"},{"groupId":"OG001","value":"2","spread":"1"},{"groupId":"OG002","value":"4","spread":"1"},{"groupId":"OG003","value":"3","spread":"1"}]}]}]},{"type":"PRIMARY","title":"Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1","description":"Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Improvement from baseline scores.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.02"},{"groupId":"OG001","value":"0.05","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"11.1","spread":null},{"groupId":"OG002","value":"11.1","spread":null},{"groupId":"OG003","value":"68.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes That Improved by One-line (5 Letters)","description":"Percentage of eyes that improved by one-line (5 letters) on the 5% contrast sensitivity chart","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"15.3","spread":null},{"groupId":"OG002","value":"37.5","spread":null},{"groupId":"OG003","value":"36.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Visual Evoked Potential P100 Latency Per Treatment Arm","description":"Visual evoked potential 60min P100 latency on dalfampridine vs. placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.6","spread":"2.4"},{"groupId":"OG001","value":"120.2","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Odds Ratio Quartile of Visual Field Index","description":"The Visual Field Index (VFI) is a global index that assigns a number between 1% to 100% based on an aggregate percentage of visual function, with 100% being a perfect age-adjusted visual field.\n\nProbability of falling in the best quartile for visual field (VFI) measures (Q1), relative to the three next quartiles for worse VFIs (Q2-4), while on Dalfampridine vs Placebo. Due to the clustered observations at different times in a cross-over design, the visual field data is not suited to a normal theory model and should not be expressed as a continuous variable. Thus, a categorical model that uses a multinomial distribution for measurement of 4 categories was selected for proper statistical modeling, with results expressed as odds ratios.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.53","spread":"29.84"},{"groupId":"OG001","value":"85.38","spread":"86.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.50","spread":"28.30"},{"groupId":"OG001","value":"86.65","spread":"22.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.71","spread":"28.57"},{"groupId":"OG001","value":"86.00","spread":"22.75"}]}]}]},{"type":"SECONDARY","title":"Changes in Color Vision Total Error Score From Baseline Based Upon the Farnsworth Munsell Hue 100 Sort Test (FM100).","description":"Dalfampridine will change color vision Total Error Scores from baseline on the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 color palettes in the correct order based upon color hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score greater than 500 indicates virtually no color discrimination. An error score of 0 indicates no errors in ordering the hues. A Total Error Score of 0 to 128 could be seen in a normal population.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","spread":null},{"groupId":"OG001","value":"-10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Dalfampridine Effect on Quality of Life Change From Baseline.","description":"Dalfampridine treatment will result in change in quality of life. The National Eye Institute Visual Function Questionnaire consists of 25 questions characterizing visual function at home and in the community. Score ranges from 100 (best) to 0 (worst).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1","description":"Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 on Dalfampridine vs Placebo. Pelli-Robson is scored based upon the numbers read on the chart converted to LogMAR units. The scale is 0.00 (worst) to 2.35 (best).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.02"},{"groupId":"OG001","value":"0.06","spread":"0.02"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity","description":"Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Change in the number of letters able to read while on Dalfampridine and Placebo relative to their baseline scores.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"1"},{"groupId":"OG001","value":"2.5","spread":"1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["Dizziness"]}}}